Stopping Ozanimod: Large Trial Follow-Up Finds Relapses Return Mildly, With No Sign of Rebound
A large post hoc analysis of the DAYBREAK trial found that only 3.3 percent of patients relapsed after stopping ozanimod, ...
A large post hoc analysis of the DAYBREAK trial found that only 3.3 percent of patients relapsed after stopping ozanimod, ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.